MARKET

BTAI

BTAI

Bioxcel Therapeutics Inc
NASDAQ
1.700
+0.100
+6.25%
After Hours: 1.710 +0.01 +0.59% 19:51 01/02 EST
OPEN
1.630
PREV CLOSE
1.600
HIGH
1.705
LOW
1.590
VOLUME
480.41K
TURNOVER
--
52 WEEK HIGH
9.26
52 WEEK LOW
1.170
MARKET CAP
37.18M
P/E (TTM)
-0.1633
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at BTAI last week (1222-1226)?
Weekly Report · 12/29/2025 09:30
Weekly Report: what happened at BTAI last week (1215-1219)?
Weekly Report · 12/22/2025 09:30
BioXcel Therapeutics Holds Annual Stockholders Meeting
TipRanks · 12/15/2025 22:47
BioXcel Therapeutics Inc. held annual shareholder meeting
Reuters · 12/15/2025 21:31
Weekly Report: what happened at BTAI last week (1208-1212)?
Weekly Report · 12/15/2025 09:33
Weekly Report: what happened at BTAI last week (1201-1205)?
Weekly Report · 12/08/2025 09:33
Award-Winning Journalist Anjalee Khemlani to Host Virtual Roundtable with Leading Medical Experts to Discuss Latest Developments in Treating Acute Agitation Related to Neuropsychiatric Conditions
Barchart · 12/03/2025 06:00
Weekly Report: what happened at BTAI last week (1124-1128)?
Weekly Report · 12/01/2025 09:31
More
About BTAI
BioXcel Therapeutics, Inc. is a biopharmaceutical company utilizing artificial intelligence to develop medicines in neuroscience. Its subsidiary, OnkosXcel Therapeutics LLC, is focused on the development of medicines in immuno-oncology. Its advanced neuroscience candidate, BXCL501, is an investigational, orally dissolving film formulation of dexmedetomidine in development for the treatment of agitation associated with psychiatric and neurological disorders. It is continuing to develop BXCL501 for the potential acute treatment of agitation associated with bipolar disorder or schizophrenia in the at-home setting and for the potential acute treatment of agitation (non-daily) associated with dementia due to probable Alzheimer’s disease in the at-home setting and in care facilities. Its advanced immuno-oncology candidate, BXCL701, is an investigational oral innate immune activator for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors.

Webull offers BioXcel Therapeutics Inc stock information, including NASDAQ: BTAI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BTAI stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BTAI stock methods without spending real money on the virtual paper trading platform.